Street Calls of the Week
Core Scientific Inc. stock (market cap: $5.54 billion) reached a significant milestone, achieving an all-time high of 18.64 USD. According to InvestingPro data, analyst price targets range from $17 to $29, suggesting continued upside potential. This marks a notable achievement for the company, reflecting positive market sentiment and investor confidence. Over the past year, Core Scientific Inc. has experienced a remarkable 50.71% increase in its stock price, with an impressive 164.52% gain in the past six months alone. The company maintains strong liquidity with a current ratio of 1.79, indicating solid financial health. This upward trend highlights the company’s growth and potential in the market, drawing attention from investors and analysts alike. The achievement of an all-time high underscores the company’s strong performance and strategic positioning within its industry, though current valuations suggest the stock may be slightly overvalued. Get access to 13 additional exclusive ProTips and comprehensive analysis with a subscription to InvestingPro.
In other recent news, Core Scientific has been at the center of several significant developments. The company recently reported its second-quarter 2025 results, missing revenue expectations but exceeding adjusted EBITDA estimates, according to Jefferies. Following this, Jefferies raised its price target for Core Scientific to $22.00 from $16.00 while maintaining a Buy rating, reflecting optimism about the company’s acquisition outlook. Meanwhile, Core Scientific’s proposed sale to CoreWeave has faced opposition from Two Seas Capital, the company’s largest active shareholder. Two Seas Capital has urged shareholders to reject the deal, citing concerns over inadequate valuation and a flawed process. CoreWeave’s CEO, Michael Intrator, confirmed there are no plans to revise the acquisition offer, which has dampened investor hopes for a better deal. Additionally, JMP Securities reiterated its Market Outperform rating for Core Scientific, noting the company’s strategic shift towards high-performance computing is progressing well. These developments highlight the ongoing debate and strategic shifts within Core Scientific.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.